Remix Therapeutics™ Appoints Linda C. Bain to Board of Directors Portfolio News / By Libby Nunan Remix Therapeutics™ Appoints Linda C. Bain to Board of Directors Read More »
Accent Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of Novel KIF18A Inhibitor ATX-295 and Receives FDA Fast Track Designation for Lead Assets ATX-295 and DHX9 Inhibitor ATX-559 Portfolio News / By Libby Nunan Accent Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of Novel KIF18A Inhibitor ATX-295 and Receives FDA Fast Track Designation for Lead Assets ATX-295 and DHX9 Inhibitor ATX-559 Read More »
Neurona Therapeutics Presents Positive Clinical Data Update from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy at American Academy of Neurology Annual Meeting Portfolio News / By Libby Nunan Neurona Therapeutics Presents Positive Clinical Data Update from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy at American Academy of Neurology Annual Meeting Read More »
Tr1X Awarded $8 Million CIRM Grant to Support TRX103 Phase 1/2a Clinical Trial for Graft-Versus-Host Disease Portfolio News / By Libby Nunan Tr1X Awarded $8 Million CIRM Grant to Support TRX103 Phase 1/2a Clinical Trial for Graft-Versus-Host Disease Read More »
Neurona Therapeutics Raises $102 Million to Fuel NRTX-1001 Phase 3 EPIC Epilepsy Trial and Advance Regenerative Cell Therapy Pipeline Portfolio News / By Libby Nunan Neurona Therapeutics Raises $102 Million to Fuel NRTX-1001 Phase 3 EPIC Epilepsy Trial and Advance Regenerative Cell Therapy Pipeline Read More »
Plexium Announces Two Oral Presentations and Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025 Portfolio News / By Libby Nunan Plexium Announces Two Oral Presentations and Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025 Read More »
Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates Portfolio News / By Libby Nunan Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates Read More »
Atavistik Bio Announces Appointment of William Sellers, M.D. to its Scientific Advisory Board Portfolio News / By Libby Nunan Atavistik Bio Announces Appointment of William Sellers, M.D. to its Scientific Advisory Board Read More »
Tr1X Announces Succession Plan: Appoints David de Vries CEO, Effective June 1; Bill Lis to Serve as Executive Chairman Portfolio News / By Libby Nunan Tr1X Announces Succession Plan: Appoints David de Vries CEO, Effective June 1; Bill Lis to Serve as Executive Chairman Read More »
Accent Therapeutics to Present Data on Lead Programs ATX-559 and ATX-295 at the 2025 American Association for Cancer Research Annual Meeting Portfolio News / By Libby Nunan Accent Therapeutics to Present Data on Lead Programs ATX-559 and ATX-295 at the 2025 American Association for Cancer Research Annual Meeting Read More »
